Anti-Human Amyloid-β (Aducanumab)

Catalogue Number: A480-LET

Manufacturer:	Leinco Technologies, Inc
Type:	Recombinant Monoclonal
Shipping Condition:	Blue Ice
Unit(s):	1 mg, 100 mg, 25 mg, 5.0 mg, 50 mg
Host name:
Clone:	BIIB037
Isotype:
Immunogen:
Application:	ELISA

Overview

Description

Description: Amyloid-β (Aβ) is a peptide that accumulates in the brains of individuals with Alzheimer's disease, forming plaques that are a hallmark of the condition. These plaques are believed to contribute to the neurodegenerative processes seen in Alzheimer's by disrupting cell function and triggering inflammatory responses. Amyloid-β is derived from the amyloid precursor protein (APP) through enzymatic cleavage. The aggregation of Aβ into oligomers and fibrils is a key pathological feature of Alzheimer's disease, making it a significant target for therapeutic interventions aimed at reducing or preventing plaque formation 1,21,2. Aducanumab is a human monoclonal antibody of the IgG1 isotype that specifically targets aggregated forms of amyloid-β. Developed by Biogen and Neurimmune, Aducanumab was designed to bind to amyloid plaques in the brain, facilitating their clearance by the immune system. Clinical studies have shown that Aducanumab can reduce amyloid plaque levels in patients with early Alzheimer's disease, potentially slowing cognitive decline. The development of Aducanumab involved identifying antibodies from healthy elderly individuals who were cognitively normal, leveraging their immune response to create a therapeutic antibody2-4.

Additional Text

Concentration

5 mg/ml

Antibody Clonality

Monoclonal, Recombinant Monoclonal

Storage Note

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Price

£121.00

-

Quantity
Unit Size

Find out about delivery